GlassScriptPhysician profile
Matthew Short Baylon
NPI 1760020077
$13,281.20
in general payments reported to CMS, 2019-2025
40 companies · $4,425 in 2025
The $4,425 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,732 · 2022: $2,257 · 2023: $2,221 · 2024: $2,646 · 2025: $4,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,799 · Education: $262 · Consulting Fee: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,799.16 |
| Education | $261.86 |
| Consulting Fee | $231.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,814.80 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,638.79 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,174.75 | 2021-2025 | |
| Optinose US, INC. | $972.47 | 2021-2025 | |
| Pfizer INC. | $687.78 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.12 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $590.44 | 2021-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $527.45 | 2021-2025 | Dupixent |
| Pharming Healthcare, INC. | $485.41 | 2021-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $483.43 | 2021-2025 | |
| Csl Behring | $408.93 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Abbvie INC. | $368.46 | 2021-2025 | |
| Amgen INC. | $363.63 | 2022-2025 | Tezspire |
| Blueprint Medicines Corporation | $361.50 | 2021-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $302.90 | 2021-2025 | Orladeyo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $298.81 | 2025 | Vtama |
| Octapharma USA, INC. | $292.98 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Adma Biomanufacturing LLC | $247.86 | 2022-2025 | |
| Kaleo, INC. | $216.63 | 2021-2023 | Auvi-Q |
| Incyte Corporation | $183.96 | 2021-2025 | Opzelura |
| Hikma Pharmaceuticals USA | $164.17 | 2023-2025 | Ryaltris |
| Grifols USA, LLC | $141.34 | 2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $132.98 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.22 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $101.21 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $99.76 | 2021-2023 | Airduo Digihaler |
| Galderma Laboratories, L.P. | $80.87 | 2025 | Nemluvio |
| Phadia US INC. | $67.40 | 2021-2023 | Immunocap |
| Covis Pharma Gmbh | $64.64 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $55.97 | 2025 | Dawnzera |
| Baxter Healthcare | $44.49 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Leo Pharma INC. | $37.13 | 2022 | |
| Merck Sharp & Dohme LLC | $23.30 | 2023 | |
| Lilly USA, LLC | $21.63 | 2025 | Ebglyss |
| Uswm, LLC | $17.12 | 2021 | |
| Seqirus USA INC | $16.37 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Cranial Technologies, INC | $15.98 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.55 | 2025 | Zoryve |
| Gc Biopharma USA, INC. | $14.04 | 2025 | Alyglo |
| Aimmune Therapeutics, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Baylon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.